Laboratory Interpretation: Severe Sepsis with Multi-Organ Dysfunction
These laboratory findings indicate severe sepsis with multi-organ dysfunction, requiring immediate aggressive resuscitation, broad-spectrum antibiotics, source control, and close monitoring for complications including acute kidney injury, metabolic derangements, and potential progression to septic shock.
Hematologic Abnormalities
The marked leukocytosis (WBC 23.13) with neutrophilia (absolute neutrophils 18.27), monocytosis (2.31), and left shift (metamyelocytes 1.0) represents a classic septic response pattern 1. The presence of immature forms (left shift) indicates bone marrow activation in response to severe infection. While leukocytosis has a broad differential 2, in the context of multi-organ dysfunction, this pattern strongly suggests sepsis rather than hematologic malignancy.
Key distinction: The lymphopenia (10%) with elevated neutrophil-to-lymphocyte ratio is characteristic of severe sepsis and correlates with worse outcomes 3. This is not the monocytosis pattern seen in chronic myelomonocytic leukemia, which would show persistent monocytosis >1,000/μL with dysplastic features 4.
Metabolic and Renal Derangements
Acute Kidney Injury
The dramatic improvement in renal function (Cr 2.84 → 0.93, BUN 50 → 23) demonstrates rapid reversal of AKI within 48 hours, which by ADQI consensus represents transient rather than persistent AKI 5. The initial eGFR of 23 indicated severe AKI, likely secondary to sepsis-induced hypoperfusion.
Management implications 5:
- The rapid reversal suggests prerenal azotemia from volume depletion rather than acute tubular necrosis
- No indication for renal replacement therapy given rapid recovery
- Drug dosing should be reassessed dynamically as renal function improves
- Avoid nephrotoxic agents (NSAIDs, aminoglycosides) during recovery phase
Severe Hyponatremia
Na 127 represents moderate-to-severe hyponatremia, likely multifactorial:
- SIADH from severe sepsis
- Volume depletion with hypotonic fluid losses
- Hyperglycemia-induced dilutional effect (each 100 mg/dL glucose elevation lowers Na by ~1.6 mEq/L)
Correction strategy: Address underlying sepsis, cautious fluid resuscitation with isotonic crystalloids, and correct hyperglycemia. Avoid overly rapid correction (>8-10 mEq/L per 24 hours) to prevent osmotic demyelination.
Hyperglycemia and Metabolic Acidosis
Glucose 358 with CO2 21 (metabolic acidosis) indicates stress hyperglycemia in sepsis. Per Surviving Sepsis Campaign guidelines, initiate insulin when two consecutive glucose values exceed 180 mg/dL, targeting glucose ≤180 mg/dL 1. Avoid tight glycemic control (target <110 mg/dL) as this increases hypoglycemia risk without mortality benefit.
The metabolic acidosis (CO2 21) likely represents lactic acidosis from septic hypoperfusion. Do not administer sodium bicarbonate for pH ≥7.15, as it does not improve hemodynamics or reduce vasopressor requirements 1.
Hepatic and Nutritional Markers
Elevated Alkaline Phosphatase
Alk phos 126 with normal AST (13) suggests cholestatic pattern rather than hepatocellular injury. In sepsis, this may indicate:
- Sepsis-associated cholestasis
- Hypoperfusion injury
- Underlying biliary pathology requiring imaging
Clinical caveat: Low alkaline phosphatase in pediatric sepsis correlates with AKI severity 6, but elevated levels in adults typically reflect cholestasis or bone turnover.
Hypoalbuminemia and Elevated Globulin
Albumin 2.9 with globulin 5.2 (A/G ratio 0.6) indicates:
- Capillary leak syndrome from sepsis (albumin loss)
- Acute phase response (elevated globulins)
- Malnutrition or chronic illness
This pattern is typical of severe sepsis and improves with source control and resolution of inflammation 7.
Immediate Management Algorithm
1. Sepsis Resuscitation 1:
- Obtain blood cultures before antibiotics
- Administer broad-spectrum antibiotics within 1 hour
- Crystalloid resuscitation 30 mL/kg for hypoperfusion
- Identify and control infection source
2. Glucose Management 1:
- Start insulin infusion for glucose >180 mg/dL
- Target glucose ≤180 mg/dL
- Monitor every 1-2 hours until stable, then every 4 hours
- Use arterial blood glucose if available (more accurate than capillary)
3. Renal Function Monitoring 5:
- Given rapid AKI reversal, continue supportive care
- Reassess drug dosing as creatinine normalizes
- Monitor for recurrent AKI (requires 48-hour sustained reversal to separate episodes)
- Avoid nephrotoxins during recovery phase
4. Electrolyte Correction:
- Correct hyponatremia gradually with isotonic fluids
- Monitor sodium every 4-6 hours during correction
- Address underlying hyperglycemia contributing to dilutional hyponatremia
5. VTE Prophylaxis 1:
- Initiate pharmacologic prophylaxis with LMWH or UFH once hemodynamically stable
- Adjust for renal function (use dalteparin or UFH if CrCl <30 mL/min)
Critical Pitfalls to Avoid
- Do not pursue tight glycemic control (target <110 mg/dL) - increases hypoglycemia without benefit 1
- Do not give bicarbonate for pH ≥7.15 - no hemodynamic benefit 1
- Do not use eGFR equations to assess renal function in AKI - inaccurate during dynamic changes 5
- Do not overlook infection source control - antibiotics alone are insufficient
- Do not rapidly correct hyponatremia - risk of osmotic demyelination syndrome
The dramatic improvement in renal function and BUN suggests appropriate initial management with fluid resuscitation and sepsis treatment. Continue monitoring for persistent organ dysfunction and adjust therapies as clinical status evolves.